Abstract:The rebound competent viral reservoir (RCVR)–virus that persists during antiretroviral treatment (ART) and can reignite systemic infection when treatment is stopped–is the primary barrier to eradicating HIV. We used time to initiation of ART during primary infection of rhesus macaques (RMs) after intravenous challenge with barcoded SIVmac239 as a means to elucidate the dynamics of RCVR establishment in groups of RMs by creating a multi-log range of pre-ART viral loads and then assessed viral time-to-rebound and reactivation rates resulting from the discontinuation of ART after one year. RMs started on ART on days 3, 4, 5, 6, 7, 9 or 12 post-infection showed a nearly 10-fold difference in pre-ART viral measurements for successive ART-initiation timepoints. Only 1 of 8 RMs initiating ART on days 3 and 4 rebounded after ART interruption despite measurable pre-ART plasma viremia. Rebounding plasma from the 1 rebounding RM contained only a single barcode lineage detected at day 50 post-ART. All RMs starting ART on days 5 and 6 rebounded between 14- and 50-days post-ART with 1–2 rebounding variants each. RMs starting ART on days 7, 9, and 12 had similar time-to-measurable plasma rebound kinetics despite multiple log differences in pre-ART plasma viral load (pVL), with all RMs rebounding between 7- and 16-days post-ART with 3–28 rebounding lineages. Calculated reactivation rates per pre-ART pVL were highest for RMs starting ART on days 5, 6, and 7 after which the rate of accumulation of the RCVR markedly decreased for RMs treated on days 9 and 12, consistent with multiphasic establishment and near saturation of the RCVR within 2 weeks post infection. Taken together, these data highlight the heterogeneity of the RCVR between RMs, the stochastic establishment of the very early RCVR, and the saturability of the RCVR prior to peak viral infection. Antiretroviral therapy (ART) stops HIV replication without impacting the "rebound-competent viral reservoir" (RCVR), comprised of persistent, already infected cells that can rekindle active HIV infection once ART is stopped. Despite much effort, the characteristics of the clinically relevant RCVR remain poorly defined. We developed a SIV-infected rhesus macaque model and studied temporal development of the RCVR during primary SIV infection, characterizing the impact of RCVR establishment dynamics on post-ART SIV rebound dynamics. Despite measurable SIV viremia, the viral dissemination that developed up to day 4 of SIV infection was highly labile, unable to form an RCVR that can mediate viral rebound after discontinuation of one year of ART. From days 5 to 7, both the extent of primary infection assessed by plasma viremia and post-ART viral reactivation rates exponentially increased in concert, but from day 7 to 12 post-infection, reactivation rates only marginally increased whereas extent of infection continued exponential expansion. This disconnect suggests that the multiphase establishment of the RCVR is saturable and therefore constitutes only a subset of overall SIV infection when ART is initiated after day 7. These observations have important implications for therapeutic targeting of the RCVR and for measuring the impact of such therapies on RCVR size in vivo .

Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption

Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells

Anti–PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers

Suppression of viral rebound by a Rev-dependent lentiviral particle in SIV-infected rhesus macaques

TGF-β blockade drives a transitional effector phenotype in T cells reversing SIV latency and decreasing SIV reservoirs in vivo

Reversal of the CD8+ T-Cell Exhaustion Induced by Chronic HIV-1 Infection Through Combined Blockade of the Adenosine and PD-1 Pathways

Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication

Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection

Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy

Control of Siv Rebound Through Structured Treatment Interruptions During Early Infection

Dynamic Decay of Viral Reservoirs in Systemic and Lymphoid Compartments of SIV-infected Rhesus Macaques on Long-Term Combined Antiretroviral Therapy

Blocking α 4 β 7 integrin delays viral rebound in SHIV SF162P3 -infected macaques treated with anti-HIV broadly neutralizing antibodies

Vedolizumab-mediated integrin α4β7 blockade does not control HIV-1SF162 rebound after combination antiretroviral therapy interruption in humanized mice

SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity

Early antiretroviral therapy in SIV-infected rhesus macaques reveals a multiphasic, saturable dynamic accumulation of the rebound competent viral reservoir

Combination of CD8β Depletion and Interleukin-15 Superagonist N-803 Induces Virus Reactivation in Simian-Human Immunodeficiency Virus-Infected, Long-Term ART-Treated Rhesus Macaques

The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques

Antiviral capacity of the early CD8 T-cell response is predictive of natural control of SIV infection: Learning in vivo dynamics using ex vivo data

Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy

Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer